PMID- 36617414
OWN - NLM
STAT- MEDLINE
DCOM- 20230607
LR  - 20230621
IS  - 1423-0003 (Electronic)
IS  - 0304-324X (Linking)
VI  - 69
IP  - 6
DP  - 2023
TI  - Why Is Rapamycin Not a Rapalog?
PG  - 657-659
LID - 10.1159/000528985 [doi]
AB  - Rapamycin (sirolimus) is an immunosuppressive drug approved by the Food and Drug 
      Administration (FDA). It is also a leading candidate for targeting aging. 
      Rapamycin and its analogs (everolimus, temsirolimus, ridaforolimus) inhibit the 
      mammalian target of rapamycin (mTOR) kinase by binding to FK506-binding proteins 
      (FKBP) and have a similar chemical structure that only differs in the functional 
      group present at carbon-40. Analogs of rapamycin were developed to improve its 
      pharmacological properties, such as low oral bioavailability and a long 
      half-life. The analogs of rapamycin are referred to as "rapalogs." Rapamycin is 
      the parent compound and should therewith not be called a "rapalog."
CI  - (c) 2023 The Author(s). Published by S. Karger AG, Basel.
FAU - Kuerec, Ajla Hodzic
AU  - Kuerec AH
AD  - Healthy Longevity Translational Research Program, Yong Loo Lin School of 
      Medicine, National University of Singapore, Singapore, Singapore, 
      dr.ajlahodzic@gmail.com.
AD  - Centre for Healthy Longevity, @AgeSingapore, National University Health System, 
      Singapore, Singapore, dr.ajlahodzic@gmail.com.
FAU - Maier, Andrea B
AU  - Maier AB
AD  - Healthy Longevity Translational Research Program, Yong Loo Lin School of 
      Medicine, National University of Singapore, Singapore, Singapore.
AD  - Centre for Healthy Longevity, @AgeSingapore, National University Health System, 
      Singapore, Singapore.
AD  - Vrije Universiteit Amsterdam, Department of Human Movement Sciences, 
      @AgeAmsterdam, Amsterdam Movement Sciences, Amsterdam, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230107
PL  - Switzerland
TA  - Gerontology
JT  - Gerontology
JID - 7601655
RN  - 0 (MTOR Inhibitors)
RN  - W36ZG6FT64 (Sirolimus)
RN  - 0 (Immunosuppressive Agents)
RN  - 9HW64Q8G6G (Everolimus)
SB  - IM
MH  - Humans
MH  - *MTOR Inhibitors
MH  - *Sirolimus/pharmacology
MH  - Immunosuppressive Agents/pharmacology
MH  - Everolimus
OTO - NOTNLM
OT  - Aging
OT  - Mammalian target of rapamycin inhibitors
OT  - Sirolimus
EDAT- 2023/01/09 06:00
MHDA- 2023/06/07 06:42
CRDT- 2023/01/08 18:23
PHST- 2022/09/07 00:00 [received]
PHST- 2022/12/22 00:00 [accepted]
PHST- 2023/06/07 06:42 [medline]
PHST- 2023/01/09 06:00 [pubmed]
PHST- 2023/01/08 18:23 [entrez]
AID - 000528985 [pii]
AID - 10.1159/000528985 [doi]
PST - ppublish
SO  - Gerontology. 2023;69(6):657-659. doi: 10.1159/000528985. Epub 2023 Jan 7.